ATE410412T1 - Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen - Google Patents

Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen

Info

Publication number
ATE410412T1
ATE410412T1 AT02764832T AT02764832T ATE410412T1 AT E410412 T1 ATE410412 T1 AT E410412T1 AT 02764832 T AT02764832 T AT 02764832T AT 02764832 T AT02764832 T AT 02764832T AT E410412 T1 ATE410412 T1 AT E410412T1
Authority
AT
Austria
Prior art keywords
compounds
analogues
preparing
oxopyrrolidine
levetiracetam
Prior art date
Application number
AT02764832T
Other languages
English (en)
Inventor
Celal Ates
John Surtees
Anne-Catherine Burteau
Violeta Marmon
Emile Cavoy
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE410412T1 publication Critical patent/ATE410412T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT02764832T 2001-08-10 2002-08-05 Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen ATE410412T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01119396 2001-08-10

Publications (1)

Publication Number Publication Date
ATE410412T1 true ATE410412T1 (de) 2008-10-15

Family

ID=8178301

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764832T ATE410412T1 (de) 2001-08-10 2002-08-05 Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen

Country Status (10)

Country Link
US (3) US7122682B2 (de)
EP (1) EP1419144B1 (de)
JP (1) JP4334344B2 (de)
AT (1) ATE410412T1 (de)
AU (1) AU2002329233B2 (de)
CA (1) CA2455155C (de)
DE (1) DE60229267D1 (de)
ES (1) ES2314090T3 (de)
IL (2) IL160045A0 (de)
WO (1) WO2003014080A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4334344B2 (ja) * 2001-08-10 2009-09-30 ユセベ ファルマ ソシエテ アノニム オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
WO2005023763A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
EP1667967B1 (de) * 2003-09-24 2012-08-01 UCB Pharma, S.A. Verfahren zur herstellung von 2-oxo-1-pyrrolidinderivaten
KR101190912B1 (ko) * 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
CA2488325C (en) 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
US20080146819A1 (en) * 2005-03-10 2008-06-19 Rubamin Limited Process for Preparing Levetiracetam
CN101263113B (zh) * 2005-09-15 2012-06-13 Ucb医药有限公司 4-取代的-吡咯烷-2-酮及其用途
US8338621B2 (en) * 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
CN101511786A (zh) * 2006-07-25 2009-08-19 Zach系统股份公司 制备左乙拉西坦的方法
EP2147911A1 (de) 2008-07-24 2010-01-27 ZaCh System S.p.A. Verfahren zur Herstellung von Levetiracetam
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
CN105968024A (zh) * 2013-06-19 2016-09-28 成都百途医药科技有限公司 一种奥拉西坦的合成方法
CN103553998B (zh) * 2013-11-06 2015-11-25 温州智创科技有限公司 (s)-奥拉西坦晶型iii的制备方法
CN103553997B (zh) * 2013-11-06 2015-11-25 温州智创科技有限公司 一种(s)-奥拉西坦晶型iii的制备方法
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
JP6872500B2 (ja) 2015-05-25 2021-05-19 エステベ・キミカ・ソシエダッド・アノニマＥｓｔｅｖｅ Ｑｕｉｍｉｃａ， Ｓ．Ａ． ブリバラセタムを製造する方法
CN106591179B (zh) * 2016-12-05 2018-07-03 长兴制药股份有限公司 甲基包囊菌及其在选择性拆分制备(S)-α-乙基-2-氧-1-吡咯烷乙酸盐上的应用
WO2019028669A1 (zh) * 2017-08-08 2019-02-14 浙江华海药业股份有限公司 一种无溶剂制备左乙拉西坦的方法
CN110799495B (zh) * 2017-08-08 2022-12-13 浙江华海药业股份有限公司 一种左乙拉西坦的合成方法
WO2019028671A1 (zh) * 2017-08-08 2019-02-14 浙江华海药业股份有限公司 一种左乙拉西坦的制备方法
CN110452157B (zh) * 2018-12-28 2020-11-03 广州市朗启医药科技有限责任公司 常山酮及其中间体的合成方法
CN113816872A (zh) * 2020-06-19 2021-12-21 浙江华海药业股份有限公司 一种（s）-2-氨基丁酰胺的合成方法
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
US12559456B2 (en) 2021-02-03 2026-02-24 Suzhou Brighthope Pharma Tech Co., Ltd Method for preparing levetiracetam and intermediates thereof
CN115260075A (zh) * 2021-03-30 2022-11-01 浙江华海药业股份有限公司 一种制备左乙拉西坦的方法
CN114409586A (zh) * 2021-12-23 2022-04-29 山东诚汇双达药业有限公司 一种左乙拉西坦的制备方法
WO2023178538A1 (zh) 2022-03-23 2023-09-28 浙江华海药业股份有限公司 一种纯化左乙拉西坦中间体的方法
US12590059B2 (en) 2023-03-28 2026-03-31 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam
US20240368082A1 (en) * 2023-05-05 2024-11-07 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam and intermediate thereof
US20240368081A1 (en) * 2023-05-05 2024-11-07 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam and intermediate thereof
US20240368080A1 (en) * 2023-05-05 2024-11-07 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam and intermediate thereof
US12528770B2 (en) 2023-06-12 2026-01-20 Suzhou Brighthope Pharmatech Co., Ltd. Process for the production of levetiracetam and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
JP4334344B2 (ja) * 2001-08-10 2009-09-30 ユセベ ファルマ ソシエテ アノニム オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用

Also Published As

Publication number Publication date
AU2002329233B2 (en) 2007-08-16
WO2003014080A2 (en) 2003-02-20
CA2455155C (en) 2012-04-10
US20040204476A1 (en) 2004-10-14
DE60229267D1 (de) 2008-11-20
JP2005507378A (ja) 2005-03-17
JP4334344B2 (ja) 2009-09-30
IL160045A (en) 2010-06-30
US7122682B2 (en) 2006-10-17
EP1419144A2 (de) 2004-05-19
WO2003014080A3 (en) 2003-11-06
US20070142647A1 (en) 2007-06-21
ES2314090T3 (es) 2009-03-16
US20060258734A1 (en) 2006-11-16
CA2455155A1 (en) 2003-02-20
EP1419144B1 (de) 2008-10-08
US7563912B2 (en) 2009-07-21
IL160045A0 (en) 2004-06-20

Similar Documents

Publication Publication Date Title
DE60229267D1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
DE59108707D1 (de) Verfahren zur Herstellung von Oxetanonen
ATE132487T1 (de) Verfahren zur herstellung von substituierten piperidinen
ATE407127T1 (de) Verfahren zur herstellung von beraprost und dessen salzen
ATE236139T1 (de) Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
ATE197150T1 (de) Verfahren zur herstellung von dihydroxypyrimidin- derivaten
ATE190614T1 (de) Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung
DE69518164D1 (de) Verfahren zur herstellung von n-(amidinophenyl pyrrolidin)-n'-beta-alanin-substituierten harnstoffen
ATE250057T1 (de) Verfahren zur herstellung von 1-(1h)- benzoquinolizin-3-on derivaten
ATE355296T1 (de) Verfahren zur herstellung von (e,z) 3-(2- aminoethoxyimino)-androstane-6,17-dione und analoge
DE60105441D1 (de) Verfahren zur herstellung von pantoprazol und zwischenprodukte dieses verfahrens
DE69929736D1 (de) Verfahren zur Herstellung von perhalogenierten fünfgliedrigen zyklischen Verbindungen
ATE281434T1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
DE60001807D1 (de) VERFAHREN ZU HERSTELLUNG VON o-FLUORIERTEN TETRAHYDROTHIOPYRAN CARBAMATEN
ATE282594T1 (de) Verfahren zur herstellung von (+)-trans-4-p- fluorophenyl-3-hydroxymethyl-1-methylpiperidin
ATE386032T1 (de) Verfahren zur herstellung von alkylmercaptomethylergolinderivaten
ATE176463T1 (de) Verfahren zur herstellung von 2-substituierten 4,6-dialkoxypyrimidinen
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
DE69814395D1 (de) Verfahren zur herstellung von alkoxyfuranon-amin-derivaten, durch dieses verfahren erhaltene verbindungen und verwendung dieser verbindungen
DE59811798D1 (de) Verfahren zur herstellung von 5-aminomethyl-2-chlorpyridinen
DE60335805D1 (de) Verfahren zur herstellung von 1,3-dioxolan-nucleosiden
DE69707603D1 (de) Verfahren zur Herstellung von N2-Arylsulfonyl-L-Argininamiden
DE50104847D1 (de) Verfahren zur herstellung chiraler verbindungen
ATE207062T1 (de) Verfahren zur herstellung von substituierten pyrimidinderivaten
ATE168688T1 (de) Verfahren zur herstellung von sulfonylharnstoffderivaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties